忍者ブログ

Healthcare

サイトメガロウイルス感染症治療市場 2034:EMA・PMDA・FDA承認、臨床試験、疫学、医薬品、新薬承認(NDA)、開発パイプライン、治療法、および企業 — DelveInsight

 

 

Request a Sample Report on Cytomegalovirus Infection Market Size


  • Featured Treatments:

    • mRNA-1647 (ModernaTX, Inc.)

    • Letermovir 480 MG [Prevymis] (Merck Sharp & Dohme LLC)

    • Pentamer(low)/gB(low)/adjuvant vaccine (GlaxoSmithKline)

    • Posoleucel (ALVR105) (AlloVir)

  • Latest clinical trial results:

    • February 2025: Takeda Pharmaceutical announces results of a safety and efficacy evaluation study of Maribavir in hematopoietic stem cell transplant (HSCT) patients .

    • December 2024: ModernaTX, Inc. announces results from a Phase 3 trial of its mRNA-1647 vaccine in healthy 16-40 year olds .

    • June 2024: SymBio Pharmaceuticals announces results from a Phase IIa trial of Brincidofovir in patients with CMV and adenovirus infections .

    • February 2024: A study from Weill Cornell Medicine suggests that an mRNA vaccine (phase 3 trial) significantly improves the immune response against CMV infection .

Find out which treatments are expected to capture the Cytomegalovirus Infection market share @Cytomegalovirus Infection Treatment Market Report

Overview of Cytomegalovirus Infection

CMV (cytomegalovirus) is classified as herpesvirus type 5 and can range from asymptomatic to fever and fatigue, and can also have serious effects on the eyes, brain, and internal organs . Although it is unlikely to develop in healthy individuals , it can cause serious complications in immunosuppressed patients .

It is estimated that 60-90% of adults have been infected with CMV, which remains latent after infection and can reactivate when the immune system is weakened .



Request a Sample Report @Cytomegalovirus Infection Market Size

  •  

 

Scope of the Cytomegalovirus Infection Market Report

  • Research period: 2020-2034

  • Target Markets: 7MM (US, EU4, UK, Japan)

  • Major companies: ModernaTX, Inc., Merck Sharp & Dohme LLC, GlaxoSmithKline, AlloVir, etc.

  • Main treatments: mRNA-1647, Letermovir 480 MG [Prevymis], Pentamer (low)/gB(low)/adjuvant vaccine, Posoleucel (ALVR105), etc.

  • Market analysis: evaluation of existing and new treatments, SWOT analysis, market entry strategies

Find out which treatments will capture Cytomegalovirus Infection market share @Cytomegalovirus Infection Treatment Market Report


Contact Information:

Himanshu

humason@delveinsight.com

info@delveinsight.com

+14699457679


About DelveInsight


DelveInsight is a leading business consultancy and market research firm focused on life sciences, supporting pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance.

 

コメント

  • Home

プロフィール

HN:
No Name Ninja
性別:
非公開

カテゴリー

P R